The escalating prevalence of chronic diseases such as cancer and coronavirus and rapid advancements in the healthcare sector will majorly foster the cell line development market.
The escalating prevalence of chronic diseases such as cancer and coronavirus and rapid advancements in the healthcare sector will majorly foster the cell line development market. Reportedly, the global cancer burden has grown to nearly 19.3 million cases and 10 million cancer deaths in 2020. Rapid growth in cancer prevalence and its severity causing millions of deaths globally will increase the adoption of cell line technologies in biological laboratories, which will facilitate pharma scientists to discover an effective medication for such chronic disease.
Growing utilization of cell line technologies in biological studying and the flourishing biotechnology sector will fuel their adoption in various drug development procedures. According to a Global Market Insights, Inc., report, global cell line development market size is expected to grow substantially in the forthcoming years. Stated below are some factors propelling its adoption in biological studying.
Wide application range in drug discovery
As per applications, the global cell line development market is categorized into research, tissue engineering, toxicity testing, and bioproduction. The drug discovery application segment is poised to surpass US$1 billion by 2026, owing to the growing demand to develop robust medication to curb surging numbers of chronic diseases. Growing incidences of cancer and autoimmune diseases globally have generated tremendous demand for effective therapeutics and medication, which will, in turn, boost the consumption of modern drugs.
Consistent investment in biologics research
High adoption of cell line development in research and drug development will help pharmaceutical scientists to come up with an effective medication for complex disease. For example, Vir Biotechnology inked an agreement with WuXi Biologics recently to develop an antibody treatment for the COVID-19 virus. This agreement will enable WuXi to administer cell line development processes, clinical manufacturing, and formulation development of antibodies, primarily introduced by Vir Biotechnologies.
To access sample pages of this report titled, “Cell Line Development Market Size By Product (Reagents & Media, Equipment {Incubator, Centrifuge, Bioreactor, Storage Equipment, Microscope}, Accessories & Consumables), By Source (Mammalian, Non-Mammalian {Insects, Amphibians}), By Cell Line (Recombinant, Hybridomas, Continuous Cell Line, Primary Cell Line), By Application (Bioproduction, Drug Discovery, Toxicity Testing, Tissue Engineering, Research) Industry Analysis Report, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2020 – 2026” in detail along with the table of contents, please click on the link below:
https://www.gminsights.com/request-sample/detail/429
Demand for accessories and consumables
Based on product, the cell line development market is classified into accessories & consumables, equipment, and reagents & media. The accessories and consumables segment held a significant revenue share of the global industry in 2019 and is estimated to grow at 15% CAGR up to 2026. Increasing expenditure to uplift the laboratory infrastructure will create high demand for accessories and consumables such as culture vessels, gloves, bottles, syringes, and others.
Requirement in cell line engineering
The primary cell lines segment, which accounted for a 19% share of the global industry in 2019, is projected to witness significant proceeds owing to widespread applications in biological studies. Additionally, technological advancements in biologics such as 3D cell culture will further facilitate research processes in laboratories.
The mammalian source segment, which was valued at over US$3 billion in 2019, is estimated to generate lucrative growth opportunities for the industry in the coming years. The growth is predominantly attributed to the scientific advancements in cell line engineering.
Leading companies in the global cell line development market are emphasizing on facility expansion and new technology introduction to scale their drug development capabilities. For instance, FUJIFILM Diosynth Biotechnologies had recently announced the expansion of its “Flexible Biomanufacturing Facility” in Texas.
MabPlex International had reportedly announced the launch of two new cell culture production lines comprising of 2,000-liter single-use bioreactors of the GE brand. With increasing focus to upgrade the existing product portfolio, the evolving competitive dynamics will positively influence the industry landscape in the coming years.
About Global Market Insights, Inc.
Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider, offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy, and biotechnology.
Contact Us:
Arun Hegde
Corporate Sales, USA
Global Market Insights, Inc.
Phone: 1-302-846-7766
Toll Free: 1-888-689-0688
Email: sales@gminsights.com
Website: https://www.gminsights.com